Sucroferric oxyhydroxide (SFOH) is a non-calcium-, iron-based phosphate binder (PB) indicated for the treatment of hyperphosphataemia in dialysis patients. The VERIFIE (Velphoro Evaluation of Real-lIfe saFety, effectIveness and adherencE) study is evaluating the safety and effectiveness of SFOH in dialysis patients in routine clinical practice. METHODS: VERIFIE is a non-interventional, prospective, multicentre, European cohort study (scheduled observation period per patient: 12-36 months; planned enrolment: 1000 patients). This interim analysis reports safety and effectiveness outcomes 18 months after first-patient, first-visit. RESULTS: Data were available for 462 patients (mean age 63.0 years; 68.2% male) included in the safety analysis set. Of those, 427 patients were included in the full analysis set for evaluation of the effectiveness of SFOH, including serum phosphorus (sP). The mean observation period was 166 days. Prior PB use was reported for 60% of patients at study entry, mainly sevelamer (56.7%), lanthanum (30.0%) and calciumbased (38.3%) PBs. Mean initial dose of SFOH was 1090.1 mg (2.2 pills/day) at baseline (BL), rising to 1212.6 mg (2.4 pills/day) at the time of last documented dose. Approx. half of patients (51.3%) received concomitant PB therapy (in addition to SFOH) during the observation period. In total, 166 patients (35.9%) reported 1 adverse drug reaction, most of which were gastrointestinal-related (Table) . One hundred and eight patients (23.4%) discontinued SFOH during the observation period. There were small, non-significant increases in mean serum ferritin from BL to Months 6 and 12, and no significant changes in TSAT or haemoglobin levels were observed. SFOH therapy was associated with significant reductions in sP from BL to Months 6 and 12 (-0.9 and -0.8 mg/dL respectively; p<0.001). The proportion of patients with sP levels 5.5 mg/dL increased from 30.0% at BL to 58.4% at Month 6, and to 48.6% at Month 12. Serum levels of iPTH and calcium remained close to BL levels during the observation period. CONCLUSIONS: SFOH was well tolerated, and no new safety risks were identified in this real-world study. In addition, SFOH was effective for reduction and maintenance of sP levels, with a low daily pill burden.
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FP594 THE USEFULNESS OF ETELCALCETIDE IN JAPANESE PATIENTS ON HEMODIALYSIS

INTRODUCTION AND AIMS:
Controlling parathyroid hormones (PTHs) is important for the prevention of kidney disease-mineral and bone disorder. However, vitamin D elevates serum calcium; and cinacalcet exacerbates gastrointestinal symptoms such as nausea, which reduces adherence and makes PTH difficult to control. Etelcalcetide, a novel intravenous calcimimetic, was released in Japan in February 2017. It is injected after hemodialysis, and therefore expected to be more effective compared to previous drugs. This prompted us to analyze the usefulness of etelcalcetide in patients on hemodialysis (HD). METHODS: Forty-two patients on HD were switched from cinacalcet to etelcalcetide from April 2017 to October 2017. The mean age was 62.9 years (range: 29-89), and the mean number of years on HD was 15.9 6 8.9 years. Cinacalcet was discontinued one day before changing to etelcalcetide. We evaluated blood tests (corrected calcium [Ca] , phosphorus [P] , and intact parathyroid hormone [i-PTH] levels) before and 2, 4, 8, 12, 16, 20 , and 24 weeks after initiation of etelcalcetide. We also analyzed the gastrointestinal symptoms (Izumo Scale: upper gastrointestinal symptoms, 0-45; lower gastrointestinal symptoms, 0-35), Bristol Stool Scale (BSS: 1-7), nutritional status (geriatric nutritional risk index [GNRI] and normalized protein catabolic rate [n PCR]), and volume of parathyroid glands. RESULTS: Serum i-PTH levels significantly declined after 12 weeks (p<0.01) and continued to decline at 24 weeks (240.7 6 139.2 vs. 125.7 6 82.1 pg/mL, p <0.01, figure) . Serum corrected Ca levels significantly decreased at 6 weeks (9.2 6 0.5 to 8.9 6 0.5 mg/ dL, p<0.05). However, after adjusting the dose of vitamin D and etelcalcetide, the corrected serum Ca levels increased to baseline level after 8 weeks. No significant differences were observed for serum phosphorus levels. The Izumo Scale scores for upper gastrointestinal symptoms significantly decreased from of 5.5 6 6.1 to 2.3 6 3.1 (p<0.01). In contrast, Izumo Scale scores for lower digestive symptoms and Bristol Stool Scale scores did not change. These data indicate that etelcalcetide had fewer gastrointestinal symptoms. The GNRI scores did not change. However, the n PCR significantly increased from 0.85 6 0.08 to 0.90 6 0.09 g/kg/day (p<0.05). The volume of parathyroid glands did not significantly change. CONCLUSIONS: In this study, etelcalcetide was significantly more effective than cinacalcet at reducing i-PTH. Moreover, etelcalcetide produced fewer upper gastrointestinal symptoms. These data suggest that changing from cinacalcet to etelcalcetide may lessen gastrointestinal symptoms and improve adherence, thus reducing i-PTH levels. Further studies are needed to clarify the long-term safety and efficacy of etelcalcetide. 
